This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, R. H. Articles by Kwon, E. D. Search for Related Content PubMed PubMed Citation Articles by Thompson, R. H. Articles by Kwon, E. D.

PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma

Authors' Affiliations: Departments of ¹ Urology, ² Immunology, ³ Health Sciences Research, and ⁴ Laboratory Medicine and Pathology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Eugene D. Kwon, Departments of Urology and Immunology, Mayo Clinic, 200 First Street, SW Rochester, MN 55905. Phone: 507-284-8371; Fax: 507-284-4987; E-mail: kwon.eugene{at}mayo.edu.

Purpose: B7-H1 is expressed by clinically aggressive forms of renal cell carcinoma (RCC) and predicts adverse outcome. B7-H1 is known to impair host immunity via interaction with the Programmed Death-1 (PD-1) receptor, which is expressed by activated T cells. Levels of immune cells expressing PD-1 (PD-1⁺) in clinical RCC tumors have not been evaluated. Thus, we tested whether immune cell PD-1 expression is observed within aggressive RCC tumors.

Experimental Design: Between 2000 and 2003, 267 patients underwent nephrectomy at our institution for clear cell RCC and had fresh-frozen tissue available for review. These RCC specimens were immunostained using anti–PD-1 (clone MIH4) and outcome analyses were conducted.

Results: Mononuclear immune cell infiltration was observed in 136 (50.9%) specimens. PD-1⁺ immune cells were present in 77 of these 136 (56.6%) tumors. In contrast, RCC tumor cells did not express PD-1. Patients with PD-1⁺ immune cells were significantly more likely to harbor B7-H1⁺ tumor cells (P < 0.001), larger tumors (P = 0.001), and tumors of higher nuclear grade (P = 0.001). Likewise, intratumoral PD-1⁺ immune cells were associated with advanced tumor-node-metastasis stage (P = 0.005), coagulative tumor necrosis (P = 0.027), and sarcomatoid differentiation (P = 0.008). With a median follow-up of 2.9 years, 52 patients died from RCC. Univariately, patients with PD-1⁺ immune cells were at significant risk of cancer-specific death compared with PD-1^– patients (risk ratio, 2.24; P = 0.004).

Conclusions: Levels of immune cells expressing PD-1 were increased in patients with high-risk RCC tumors. Interactions between immune cell PD-1 and B7-H1 may promote cancer progression by contributing to immune dysfunction in patients with RCC.

This article has been cited by other articles:

				J. Carreras, A. Lopez-Guillermo, G. Roncador, N. Villamor, L. Colomo, A. Martinez, R. Hamoudi, W. J. Howat, E. Montserrat, and E. Campo High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma J. Clin. Oncol., March 20, 2009; 27(9): 1470 - 1476. [Abstract] [Full Text] [PDF]

				R. H. Thompson, X. Zang, C. M. Lohse, B. C. Leibovich, S. F. Slovin, V. E. Reuter, J. C. Cheville, M. L. Blute, P. Russo, E. D. Kwon, et al. Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage Cancer Res., August 1, 2008; 68(15): 6054 - 6058. [Abstract] [Full Text] [PDF]

				S. A. Boorjian, Y. Sheinin, P. L. Crispen, S. A. Farmer, C. M. Lohse, S. M. Kuntz, B. C. Leibovich, E. D. Kwon, and I. Frank T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival Clin. Cancer Res., August 1, 2008; 14(15): 4800 - 4808. [Abstract] [Full Text] [PDF]

				R. Yamamoto, M. Nishikori, T. Kitawaki, T. Sakai, M. Hishizawa, M. Tashima, T. Kondo, K. Ohmori, M. Kurata, T. Hayashi, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma Blood, March 15, 2008; 111(6): 3220 - 3224. [Abstract] [Full Text] [PDF]

				T. Okazaki and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int. Immunol., July 2, 2007; (2007) dxm057v1. [Abstract] [Full Text] [PDF]